OBP2B (odorant binding protein 2B) is presumed to bind and transport small hydrophobic volatile molecules 1, consistent with its annotation in olfactory sensory perception. However, recent large-scale genetic studies reveal OBP2B has unexpected systemic relevance beyond chemosensation. Proteome-wide Mendelian randomization identified OBP2B among 20 circulating proteins associated with venous thromboembolism (VTE) risk 2. Genome-wide association studies have implicated OBP2B in kidney function decline, with an OBP2B-containing polygenic risk score predicting chr9 kidney disease in East Asian populations 3. Additionally, lower circulating OBP2B levels were associated with increased multiple myeloma risk in bidirectional Mendelian randomization analyses 4. OBP2B also emerged as a potential causal factor in glaucoma pathogenesis 5 and demonstrated pleiotropic associations with Alzheimer's disease and cardiovascular traits 6. Transcriptionally, OBP2B is co-regulated by an ABO blood group regulatory element at +22.6 kb, suggesting coordinate expression control 1. OBP2B was identified as a hub gene in obstructive sleep apnea treatment response 7. These findings indicate OBP2B functions beyond olfaction, with circulating levels potentially serving as biomarkers for vascular, renal, hematologic, and neurological diseases.